Thousands more vulnerable people are eligible to receive the UK’s second antiviral Paxlovid, which has been added to the PANORAMIC national study. Paxlovid reduced the risk of hospitalisation or death by 88% in clinical trials and is already available directly through the NHS to highest-risk patients The UK has procured […]
Pharmaceutical company Merck applied on October 11 for FDA emergency use authorization for its oral antiviral COVID-19 drug, molnupiravir. In this Q&A, Carl Dieffenbach, PhD, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, and Joshua Sharfstein, MD, talk about the development of the medication, how […]
Un caro cóctel de anticuerpos ajenos evita una muerte por cada 17 pacientes tratados, según los resultados del mayor ensayo clínico del mundo. La humanidad desarrolló en tiempo récord vacunas para evitar la covid, pero acumula fracasos en la carrera para encontrar un tratamiento eficaz para las personas que ya tienen […]
A single pill of the investigational drug molnupiravir taken twice a day for 5 days eliminated SARS-CoV-2 from the nasopharynx of 49 participants. That led Carlos del Rio, MD, distinguished professor of medicine at Emory University in Atlanta, Georgia, to suggest a future in which a drug like molnupiravir could be […]
A single pill of the investigational drug molnupiravir taken twice a day for 5 days eliminated SARS-CoV-2 from the nasopharynx of 49 participants. That led Carlos del Rio, MD, distinguished professor of medicine at Emory University in Atlanta, Georgia, to suggest a future in which a drug like molnupiravir could be […]
A single pill of the investigational drug molnupiravir taken twice a day for 5 days eliminated SARS-CoV-2 from the nasopharynx of 49 participants. That led Carlos del Rio, MD, distinguished professor of medicine at Emory University in Atlanta, Georgia, to suggest a future in which a drug like molnupiravir could be […]
A single pill of the investigational drug molnupiravir taken twice a day for 5 days eliminated SARS-CoV-2 from the nasopharynx of 49 participants. That led Carlos del Rio, MD, distinguished professor of medicine at Emory University in Atlanta, Georgia, to suggest a future in which a drug like molnupiravir could be […]
Science’s COVID-19 reporting is supported by the Heising-Simons Foundation. In March 2020, as the scope of the COVID-19 pandemic was coming into view, Jen Nwankwo and colleagues turned a pair of artificial intelligence (AI) tools against SARS-CoV-2. One newly developed AI program, called SUEDE, digitally screens all known druglike compounds […]
